MiNK Therapeutics, Inc. (INKT) vs PDS Biotechnology Corporation (PDSB)

A side-by-side comparison of MiNK Therapeutics, Inc. and PDS Biotechnology Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

INKT

MiNK Therapeutics, Inc.

$60M

$12.06HealthcareDelayed quote: Oct 6, 2026, 12:24 PM EDT

PDSB

PDS Biotechnology Corporation

$60M

$1.07HealthcareDelayed quote: Oct 6, 2026, 12:20 PM EDT

Total return — INKT vs PDSB

growth of $100 · dividends reinvested · last 5y

INKT -89.8% (-36.7%/yr)PDSB -91.2% (-38.5%/yr)INKT compounded faster over this window

INKT PDSB

INKT vs PDSB: by the numbers

•INKT is the larger company ($60M vs $60M market cap).

Metrics side by side

Profitability

Metric	INKT	PDSB
Gross margin	0.00%	0.00%
Operating margin	0.00%	0.00%
Net margin	0.00%	0.00%
ROIC	-604.20%	-3699.99%

Growth (annualized)

Metric	INKT	PDSB
Total return CAGR (5Y)	N/A	-39.13%

Go deeper

Full INKT analysis Full PDSB analysis Interactive comparison tool

Dig into the metrics

MiNK Therapeutics ROE PDS Biotechnology ROE MiNK Therapeutics operating margin PDS Biotechnology operating margin MiNK Therapeutics revenue growth PDS Biotechnology revenue growth MiNK Therapeutics free cash flow PDS Biotechnology free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.